Furthermore, high expression of CTLA-4 on TILs was significantly associated with a pCR and a better chemotherapy response (OR = 7.94, 95% CI: 0.9–70.12, p = 0.06) based on the MDACC Residual Cancer Burden Index in our cohort with TNBC. This evidence concerns the gene CTLA4 and cancer.